FR2883477B1 - Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes - Google Patents

Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes

Info

Publication number
FR2883477B1
FR2883477B1 FR0502919A FR0502919A FR2883477B1 FR 2883477 B1 FR2883477 B1 FR 2883477B1 FR 0502919 A FR0502919 A FR 0502919A FR 0502919 A FR0502919 A FR 0502919A FR 2883477 B1 FR2883477 B1 FR 2883477B1
Authority
FR
France
Prior art keywords
tritoqualine
esophageal
treatment
novel use
particularly gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0502919A
Other languages
English (en)
Other versions
FR2883477A1 (fr
Inventor
Gaetan Terrasse
Emile Loria
Mike Nicolaou
Yves Trehin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHRYSALIS PHARMA SAS, FR
Original Assignee
Gaetan Terrasse
Emile Loria
Mike Nicolaou
Yves Trehin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36087360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2883477(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gaetan Terrasse, Emile Loria, Mike Nicolaou, Yves Trehin filed Critical Gaetan Terrasse
Priority to FR0502919A priority Critical patent/FR2883477B1/fr
Priority to PCT/FR2006/000647 priority patent/WO2006100392A1/fr
Publication of FR2883477A1 publication Critical patent/FR2883477A1/fr
Application granted granted Critical
Publication of FR2883477B1 publication Critical patent/FR2883477B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
FR0502919A 2005-03-24 2005-03-24 Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes Expired - Fee Related FR2883477B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0502919A FR2883477B1 (fr) 2005-03-24 2005-03-24 Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes
PCT/FR2006/000647 WO2006100392A1 (fr) 2005-03-24 2006-03-23 Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflammatoires digestives et plus particulierement gastriques et oesophagiennes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502919A FR2883477B1 (fr) 2005-03-24 2005-03-24 Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes

Publications (2)

Publication Number Publication Date
FR2883477A1 FR2883477A1 (fr) 2006-09-29
FR2883477B1 true FR2883477B1 (fr) 2009-03-06

Family

ID=36087360

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0502919A Expired - Fee Related FR2883477B1 (fr) 2005-03-24 2005-03-24 Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes

Country Status (2)

Country Link
FR (1) FR2883477B1 (fr)
WO (1) WO2006100392A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896156A1 (fr) * 2006-01-17 2007-07-20 Gaetan Terrasse Nouvelle utilisation de la tritoqualine en association avec des substances medicamenteuses antagonistes du recepteur h2 a l'histamine,pour le traitement des maladies inflammatoires digestives
US8207188B2 (en) * 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
EP2170317A4 (fr) * 2007-02-12 2011-03-23 Mike Nicolaou Traitement de la maladie pulmonaire obstructive chonique (mpoc), du reflux gastro-oesophagien pathologique (gerd), des allergies alimentaires et autres affections et troubles gastro-intestinaux attenues par une gestion appropriee de l'histamine au moyen d'une combinaison d'inhibiteurs d'histidine decarboxylase, de medicamen
FR3048883B1 (fr) * 2016-03-18 2020-10-02 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752893A (en) * 1971-04-02 1973-08-14 American Cyanamid Co Method for inhibiting gastric acid secretion in mammals
US4103089A (en) * 1977-07-01 1978-07-25 Merrell Toraude Et Compagnie α-Acetylene and α-vinyl derivatives of amino acids

Also Published As

Publication number Publication date
FR2883477A1 (fr) 2006-09-29
WO2006100392A1 (fr) 2006-09-28

Similar Documents

Publication Publication Date Title
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
FR15C0046I2 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
HK1106803A1 (en) Meta-and para-aramid pulp and processes of making same
IS8530A (is) Meðferð á truflunum í auga þar með talinni sjóndepilsrýrnun
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
EP1778245A4 (fr) Bloqueurs de canal calcique de type t et traitement de maladies
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
NO20045554L (no) Fremgangsmate for behandling av diabetes
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
GB0413068D0 (en) Treatment of pulp
FR2883477B1 (fr) Nouvelle utilisation de la tritoqualine pour le traitement des maladies inflamatoires digestives et plus particulierement gastriques et oesophagiennes
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
MA28809B1 (fr) Utilisation de conjugues specifiques de cellule pour le traitement de maladies inflammatoires du tractus gastro-intestinal
FR2868305B1 (fr) Procede de traitement capillaire et utilisation dudit procede
FR2868306B1 (fr) Procede de traitement capillaire et utilisation dudit procede
GB0526394D0 (en) Treatment of inflammatory diseases
FR2868307B1 (fr) Utilisation de beta-endorphine pour le traitement des rides

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091130

RN Application for restoration

Effective date: 20140513

IC Decision of the director general to declare irreceivable or to reject an appeal

Effective date: 20140716

RU Appeal formed before the court of appeals

Effective date: 20141029

TP Transmission of property

Owner name: CHRYSALIS PHARMA SAS, FR

Effective date: 20141223

JE Final juridical decision affecting the existence or validity of an industrial property right

Effective date: 20150320